Verve Therapeutics (VERV) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Verve Therapeutics in November 2026.
Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
Verve Therapeutics (VERV) Stock Forecast
Analyst price target, next 12 months
$26.50
+138.1% vs today's $11.13
Price range over the last 12 months
Close to its 12-month high
Analysts covering Verve Therapeutics have a consensus 12-month target of $26.50, above the current price of $11.13.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Jul 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding VERVE's stock with a target price of $26.5, indicating potential growth.
Financial Health
VERVE Therapeutics is generating modest revenue and cash flow, indicating reasonable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.